Adverse event totals12

The totals the trial posted for each group.

1 to 12 of 12

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo
Total, all-cause mortality	Sitagliptin 100 mg
Total, all-cause mortality	Fasiglifam 25 mg
Total, all-cause mortality	Fasiglifam 50 mg
Total, other adverse events	Placebo	17	132
Total, other adverse events	Sitagliptin 100 mg	16	260
Total, other adverse events	Fasiglifam 25 mg	18	263
Total, other adverse events	Fasiglifam 50 mg	20	260
Total, serious adverse events	Placebo	2	132
Total, serious adverse events	Sitagliptin 100 mg	10	260
Total, serious adverse events	Fasiglifam 25 mg	14	263
Total, serious adverse events	Fasiglifam 50 mg	4	260

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01549964/event-totals